# A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

> **NCT03698448** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **AlgiPharma AS**

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** OligoG Dry powder for inhalation

## Key facts

- **NCT ID:** NCT03698448
- **Lead sponsor:** AlgiPharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Determined not feasible
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698448, "A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03698448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*